Amicus Therapeutics
FOLD
About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Employees: 499
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
54% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $1.56M
46% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 81
3.05% more ownership
Funds ownership: 100.67% [Q1] → 103.72% (+3.05%) [Q2]
4% less funds holding
Funds holding: 280 [Q1] → 268 (-12) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]
24% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 46
27% less capital invested
Capital invested by funds: $2.53B [Q1] → $1.83B (-$694M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Morgan Stanley
Jeffrey Hung
|
$108
|
Overweight
Upgraded
|
17 Jul 2025 |
Financial journalist opinion
Based on 6 articles about FOLD published over the past 30 days
